Merck to Bristol-Myers Face More Threats on India Drug Patents

#Bayer AG : Corporate Crimes
▻http://www.corporatewatch.org/?lid=320

5.1. Bayer and War Crimes
5.2. Scams, Blags and Corporate Bullying
5.3. Pharmaceutical Phailings
5.4. Pesticides and Poisons
5.5. Abusing Workers

Bayer CEO Marijn Dekkers explains: Nexavar cancer drug is for "western patients who can afford it.” | Knowledge Ecology International
▻http://keionline.org/node/1910

Apparently the December 3, 2013 quote is from an earlier largely overlooked event hosted by the FT. For more context, note that the Bayer price for Nexavar was $65 thousand USD, per year, in India, and that Bayer is currently arguing that the $65 thousand price is “reasonable affordable” to the India Supreme Court.
For more on backgrouond on the Nexavar case, see: ▻http://keionline.org/search/node/nexavar

Big pharma’s continued attack on India, ’pharmacy of the developing world’ | msfaccess.org
▻http://www.msfaccess.org/content/infographics-big-pharmas-continued-attack-india-pharmacy-developing-world

http://www.msfaccess.org/sites/default/files/MSF_assets/Access/Photos/ACESS_Novartis_InfographicPriceComparison_0.jpg

Novartis and Bayer are both charging exhorbitant prices for medicines in India as they continue their fight against the country’s patent law that puts people over profits in the name of access to affordable medicines. These cases both could have a major impact on MSF’s work in the field, as we rely heavily on affordable medicines produced in India to do our work.

correction (plus ou moins) de la citation ici ▻http://seenthis.net/messages/223501

et maintenant on a la transcription complète (cf lien ci-dessus)